{
  "docId": "019de071-be30-70fc-a858-8f20c51da6b3",
  "docSlug": "a62013e96cbc38ce4e129c5b57bb4496",
  "documentTitle": "Chimerix | Investor Conference Presentation Deck | 32 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 32,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide details specific RANO criteria for glioma assessment and censoring rules for efficacy analysis.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-be30-70fc-a858-8f20c51da6b3/7",
  "deckHref": "/decks/019de071-be30-70fc-a858-8f20c51da6b3",
  "deckJsonHref": "/decks/019de071-be30-70fc-a858-8f20c51da6b3.json",
  "deckAnchorHref": "/decks/019de071-be30-70fc-a858-8f20c51da6b3#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.07,
        "y": 0.00175
      },
      "kind": "list",
      "text": "Primary Endpoint: Overall response rate by RANO-HGG criteria. Secondary Endpoints: Overall response rate by RANO-LGG criteria, Duration of response, Time to response, Best overall response, Disease Control Rate, Progression-free survival, Overall survival, Corticosteroid response rate, Performance status response rate.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62c6e8c6-dbc7-4c68-b464-387167c70d72",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.56,
        "y": 0.00175
      },
      "kind": "list",
      "text": "Analysis: First 50 patient enrolled who meet eligibility for integrated efficacy analysis. Censored for all endpoints except overall survival upon eligibility criteria initiation of any additional anti-cancer therapy.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "99ea0f1a-2f71-49c3-b7d9-47edb69933ce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.1,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1Assessed by RANO-HGG and RANO-LGG criteria with dual-reader blinded independent central review (BICR). 2As discussed and prespecified with regulatory authorities",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "34ff1387-771f-4723-964f-640850d7f65e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.16,
        "x": 0.04,
        "y": 0.03
      },
      "kind": "title",
      "text": "Endpoints",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2b6a1f3-86d4-499a-8da1-d70c53c8ada1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}